LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 373-376

  Corsetti, James P ^a   Gansevoort, Ron T ^b   Navis, GerJan ^b   Sparks, Charles E ^a   Dullaart, Robin P F ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

C reactive protein; Cardiovascular disease; Cholesteryl ester transfer protein; D9N polymorphism; HDL cholesterol; Lipoprotein lipase; TaqIB polymorphisms

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; PROTEIN;

ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL ASSESSMENT; COHORT ANALYSIS; FEMALE; HIGH RISK PATIENT; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOPROTEIN LIPASE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 79151480742     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.029     Document Type: Article

References (15)

1. Corsetti J.P., Gansevoort R.T., Sparks C.E., Dullaart R.P.F. HDL protection against primary cardiac risk is lost with inflammation. Eur J Clin Invest 2010, 40:483-489.
2. Corsetti J.P., Ryan D., Rainwater D.L., Moss A.J., Zareba W., Sparks C.E. Decreased CETP activity associates with recurrent risk in postinfarction patients with high HDL cholesterol and high CRP. Atheroscler Thromb Vasc Biol 2010, 30:1657-1664.
3. Corsetti J.P., Ryan D., Moss A.J., Zareba W., Sparks C.E. NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis 2007, 196:461-468.
4. Dullaart R.P.F., Sluiter W. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics 2008, 9:747-763.
5. Sagoo G.S., Tatt I., Salanti G., et al. Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. Am J Epidemiol 2008, 168:1233-1246.
6. Pinto-Sietsma S.J., Janssen W.M.T., Hillege H.L., Navis G., de Jong P.E. Urinary albumin excretion is associated with renal functional abnormalities in a non-diabetic population. J Am Soc Nephrol 2000, 11:1882-1888.
7. Lambers Heerspink H.J., Brantsma A.H., de Zeeuw D., Bakker S.J., de Jong P.E., Gansevoort R.T. Albuminuria assessed from first-morning-void urine samples versus 24 hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008, 168:897-905.
8. Verhave J.D., Gansevoort R.T., Hillege H.L., Bakker S.J., de Zeeuw D., de Jong P.E. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004, 66:S18-S21.
9. Borggreve S.E., Hillege H.L., Wolffenbuttel B.H.R., et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006, 91:3382-3388.
10. Stein Y., Stein O. Lipoprotein lipase and atherosclerosis. Atherosclerosis 2003, 170:1-9.
11. Wang H., Eckel R.H. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009, 297:E271-E288.
12. Murdoch S.J., Breckenridge W.C. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 1995, 118:193-212.
13. Borggreve S.E., De Vries R., Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051-1069.
14. Devaraj S., Singh U., Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009, 55:229-238.
15. Shao B., Oda M.N., Oram J.F., Heinecke J.W. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010, 23:447-454.